Preferred Label : tafasitamab;
CISMeF synonym : MOR208 monoclonal antibody; XmAb5574; tafasitamab-cxix;
MeSH hyponym : XMAB-5574; MOR-00208; MOR-208; MOR00208;
UNII : QQA9MLH692;
Origin ID : C000613469;
UMLS CUI : C5139916;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-acces-derogatoire/tafasitamab-200-mg-poudre-pour-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
infusions, intravenous
tafasitamab
tafasitamab
drug information
adult
lymphoma, large B-Cell, diffuse
---
https://www.has-sante.fr/jcms/p_3312609/fr/minjuvi
https://www.has-sante.fr/jcms/p_3312620/fr/decision-n-0028-2022/dc/sem-du-27-janvier-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-minjuvi
2022
false
false
false
France
treatment outcome
drug therapy, combination
Lenalidomide
adult
lymphoma, large B-Cell, diffuse
package leaflet
summary of product characteristics
guidelines for drug use
tafasitamab
tafasitamab
infusions, intravenous
tafasitamab
continuity of patient care
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3330896/fr/minjuvi-tafasitamab-lymphome
2022
false
false
false
France
evaluation of the transparency committee
Lymphoma
lymphoma
tafasitamab
malignant lymphoma, nos
tafasitamab
---
https://www.cadth.ca/fr/tafasitamab
2021
false
false
false
Canada
French
English
drug evaluation
insurance, health, reimbursement
tafasitamab
tafasitamab
lymphoma, large B-Cell, diffuse
antineoplastic combined chemotherapy protocols
Lenalidomide
Lenalidomide/Tafasitamab Regimen
adult
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
---